Marksans Pharma · NSE: MARKSANS · BSE: 524404
Q1 FY22 results · Apr–Jun 2021
Marksans Pharma reported revenue from operations of ₹348.96 crore (up 5.4% from Q1 FY21) and net profit of ₹62.60 crore (up 26.8% from Q1 FY21) for Q1 FY22 (Apr–Jun 2021), on a consolidated basis.
| Item | Q1 FY22 | Q1 FY21 | YoY | Q4 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 348.96 | 331.15 | +5.4% | 330.20 | +5.7% |
| Other income | 5.88 | 0.18 | 32x | 6.01 | −2.1% |
| Total income | 354.85 | 331.33 | +7.1% | 336.21 | +5.5% |
| Profit before tax | 74.78 | 61.40 | +21.8% | 97.22 | −23.1% |
| Net profit for the period | 62.60 | 49.37 | +26.8% | 79.50 | −21.3% |
| EPS, basic (₹) | 1.51 | 1.20 | +25.8% | 1.93 | −21.8% |
| Net margin (%) | 17.9 | 14.9 | 24.1 |
| Item | Q1 FY22 | Q1 FY21 | YoY | Q4 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 147.22 | 155.96 | −5.6% | 137.58 | +7.0% |
| Other income | 13.94 | 0.05 | 284x | 11.91 | +17.1% |
| Total income | 161.16 | 156.01 | +3.3% | 149.49 | +7.8% |
| Profit before tax | 34.18 | 24.92 | +37.1% | 32.40 | +5.5% |
| Net profit for the period | 28.91 | 22.06 | +31.1% | 23.69 | +22.0% |
| EPS, basic (₹) | 0.71 | 0.54 | +31.5% | 0.58 | +22.4% |
| Net margin (%) | 19.6 | 14.1 | 17.2 |
Consolidated
- Filed with BSE
- 11 Aug 2021, 15:36 IST
- Board meeting
- 11 Aug 2021
- Period
- 01 Apr 2021 to 30 Jun 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 11 Aug 2021, 15:36 IST
- Board meeting
- 11 Aug 2021
- Period
- 01 Apr 2021 to 30 Jun 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE